RT info:eu-repo/semantics/article
T1 Rho-kinase inhibitors for the treatment of refractory diabetic macular oedema
A1 Mateos Olivares, Milagros
A1 García Onrubia, Luis
A1 Valentín Bravo, Francisco Javier
A1 González Sarmiento, Rogelio
A1 López Gálvez, María Isabel
A1 Pastor Jimeno, José Carlos
A1 Usategui Martín, Ricardo
A1 Pastor Idoate, Salvador
K1 Diabetic retinopathy
K1 Retina - Enfermedades
K1 Diabetes - Complicaciones y secuelas
K1 Protein kinases
K1 Ojos - Enfermedades
K1 Diabetic macular oedema
K1 3201.09 Oftalmología
AB Diabetic macular oedema (DMO) is one of the leading causes of vision loss associated with diabetic retinopathy (DR). New insights in managing this condition have changed the paradigm in its treatment, with intravitreal injections of antivascular endothelial growth factor (anti-VEGF) having become the standard therapy for DMO worldwide. However, there is no single standard therapy for all patients DMO refractory to anti-VEGF treatment; thus, further investigation is still needed. The key obstacles in developing suitable therapeutics for refractory DMO lie in its complex pathophysiology; therefore, there is an opportunity for further improvements in the progress and applications of new drugs. Previous studies have indicated that Rho-associated kinase (Rho-kinase/ROCK) is an essential molecule in the pathogenesis of DMO. This is why the Rho/ROCK signalling pathway has been proposed as a possible target for new treatments. The present review focuses on the recent progress on the possible role of ROCK and its therapeutic potential in DMO. A systematic literature search was performed, covering the years 1991 to 2021, using the following keywords: “rho-Associated Kinas-es”, “Diabetic Retinopathy”, “Macular Edema”, “Ripasudil”, “Fasudil” and “Netarsudil”. Better insight into the pathological role of Rho-kinase/ROCK may lead to the development of new strategies for refractory DMO treatment and prevention.
PB MDPI
SN 2073-4409
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59414
UL https://uvadoc.uva.es/handle/10324/59414
LA eng
NO Cells 2021, Vol. 10, Nº. 7, 1683
NO Producción Científica
DS UVaDOC
RD 17-jul-2024